Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine

Guilherme Nader Marta, Advanced Clinical Fellow – Dana-Farber Cancer Institute, shared a post on LinkedIn:

“DESTINY-Breast06 trial out in The New England Journal of Medicine

T-DXd improved median PFS to 13.2 mos vs 8.1 mos w/ chemo (HR 0.62, CI 0.51–0.74) in HR+/HER2-low mBC after 1-2 lines of ET

Consistent results in the HER2-ultralow population (HR 0.78, CI 0.5-1.2)

OS data immature.”

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Authors: Aditya Bardia,  Xichun Hu, Rebecca Dent,  Kan Yonemori, Carlos H. Barrios,  Joyce A. O’Shaughnessy, Hans Wildiers, Jean-Yves Pierga,  Qingyuan Zhang, Cristina Saura,  Laura Biganzoli, Joohyuk Sohn,  Seock-Ah Im, Christelle Lévy, William Jacot,  Natasha Begbie, Jun Ke,  Gargi Patel, and Giuseppe Curigliano.

Source: Guilherme Nader Marta/X